MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial Tara SmithFebruary 12, 2024
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011 Tara SmithJune 6, 2023